Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael Zapolin as chief executive officer. Zapolin, known as "Zappy," will be responsible for financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. The transition from former CEO Richard Buzbuzian is already underway, with the company targeting a public listing effective in the next quarter. For Quantum BioPharma, the leadership change at Unbuzzd is not merely a personnel update; it signals a strategic pivot toward scaling a consumer product that could generate substantial royalty revenue for the biopharmaceutical company.
Unbuzzd markets unbuzzd™, a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms. The company says the product is backed by a peer-reviewed clinical study and is currently available through Amazon and its website. With Zapolin at the helm, Unbuzzd aims to transition from a direct-to-consumer e-commerce play to a broader retail and commercial presence. Zapolin's mandate to secure financing and a stock exchange listing suggests that Unbuzzd is preparing for a significant capital infusion to fund marketing and distribution at scale. A successful listing would provide the company with greater visibility and access to public markets, potentially accelerating its growth trajectory.
Quantum BioPharma retains ownership of 19.84% of Unbuzzd as of March 31, 2026, according to the announcement. The agreement between the two companies includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once that threshold is reached, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. This structure means that Unbuzzd's commercial success directly benefits Quantum's bottom line, making the appointment of a CEO with a mandate to scale the business a material development for Quantum shareholders.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.), led by industry veterans.
The appointment of Zapolin, a seasoned entrepreneur with a track record in launching and scaling consumer brands, could be the catalyst Unbuzzd needs to capture a larger share of the functional beverage market. As alcohol consumption patterns evolve and consumers increasingly seek products that mitigate the negative effects of drinking, unbuzzd™ is positioned in a niche with growing demand. A nationwide rollout backed by a public listing could rapidly expand its availability beyond Amazon and its own website, driving sales and, consequently, royalty payments to Quantum. Investors in Quantum BioPharma will be watching closely to see whether Unbuzzd's public listing and marketing push translate into accelerated revenue growth.
The full press release can be viewed at https://ibn.fm/CBNq1. The latest news and updates relating to QNTM are available in the company's newsroom at Quantum BioPharma Ltd..
InvestorWire, a specialized communications platform, distributed the announcement. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For more information, visit InvestorWire. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
